Contact
searchSearch
HMP Global
Login

Non-Hodgkin Lymphomas

Non-Hodgkin Lymphoma
Specialty Channel
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
The longest reported follow-up of patients treated with CD19-directed CAR T-cell therapy demonstrated that a single infusion of tisagenlecleucel induced durable remissions in relapsed or refractory B-cell non-Hodgkin lymphoma, with no disease...
The longest reported follow-up of patients treated with CD19-directed CAR T-cell therapy demonstrated that a single infusion of tisagenlecleucel induced durable remissions in relapsed or refractory B-cell non-Hodgkin lymphoma, with no disease...
The longest reported follow-up...
06/25/2026
Oncology
News
In Vivo CAR T-Cell Therapy Shows Encouraging Early Activity in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
06/16/2026
Emily Estrada
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1...
06/16/2026
Oncology
News
BAFF-R–Targeted CAR T Therapy Shows Durable Complete Responses in Relapsed B-Cell Lymphoma
06/11/2026
Emily Estrada
Results from a phase 1 study demonstrated that PMB-CT01 elicited durable complete responses with a favorable safety profile in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study demonstrated that PMB-CT01 elicited durable complete responses with a favorable safety profile in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study...
06/11/2026
Oncology
News
Lenalidomide Plus Rituximab Maintains Survival Benefit in R/R Indolent Non-Hodgkin Lymphomas
05/21/2026
Stephanie Holland
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from...
05/21/2026
Oncology
News
Safety Outcomes of Bendamustine Treatment Among Patients With Indolent Non-Hodgkin Lymphoma in Real-World Setting
03/22/2024

Jordan Kadish

Jordan Kadish
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial...
03/22/2024
Oncology

News

News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
The longest reported follow-up of patients treated with CD19-directed CAR T-cell therapy demonstrated that a single infusion of tisagenlecleucel induced durable remissions in relapsed or refractory B-cell non-Hodgkin lymphoma, with no disease...
The longest reported follow-up of patients treated with CD19-directed CAR T-cell therapy demonstrated that a single infusion of tisagenlecleucel induced durable remissions in relapsed or refractory B-cell non-Hodgkin lymphoma, with no disease...
The longest reported follow-up...
06/25/2026
Oncology
News
In Vivo CAR T-Cell Therapy Shows Encouraging Early Activity in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
06/16/2026
Emily Estrada
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1...
06/16/2026
Oncology
News
BAFF-R–Targeted CAR T Therapy Shows Durable Complete Responses in Relapsed B-Cell Lymphoma
06/11/2026
Emily Estrada
Results from a phase 1 study demonstrated that PMB-CT01 elicited durable complete responses with a favorable safety profile in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study demonstrated that PMB-CT01 elicited durable complete responses with a favorable safety profile in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study...
06/11/2026
Oncology
News
Lenalidomide Plus Rituximab Maintains Survival Benefit in R/R Indolent Non-Hodgkin Lymphomas
05/21/2026
Stephanie Holland
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from...
05/21/2026
Oncology
News
Safety Outcomes of Bendamustine Treatment Among Patients With Indolent Non-Hodgkin Lymphoma in Real-World Setting
03/22/2024

Jordan Kadish

Jordan Kadish
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial...
03/22/2024
Oncology

Interactive Features

Recent News

News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
The longest reported follow-up of patients treated with CD19-directed CAR T-cell therapy demonstrated that a single infusion of tisagenlecleucel induced durable remissions in relapsed or refractory B-cell non-Hodgkin lymphoma, with no disease...
The longest reported follow-up of patients treated with CD19-directed CAR T-cell therapy demonstrated that a single infusion of tisagenlecleucel induced durable remissions in relapsed or refractory B-cell non-Hodgkin lymphoma, with no disease...
The longest reported follow-up...
06/25/2026
Oncology
News
In Vivo CAR T-Cell Therapy Shows Encouraging Early Activity in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
06/16/2026
Emily Estrada
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1...
06/16/2026
Oncology
News
BAFF-R–Targeted CAR T Therapy Shows Durable Complete Responses in Relapsed B-Cell Lymphoma
06/11/2026
Emily Estrada
Results from a phase 1 study demonstrated that PMB-CT01 elicited durable complete responses with a favorable safety profile in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study demonstrated that PMB-CT01 elicited durable complete responses with a favorable safety profile in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study...
06/11/2026
Oncology
News
Lenalidomide Plus Rituximab Maintains Survival Benefit in R/R Indolent Non-Hodgkin Lymphomas
05/21/2026
Stephanie Holland
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from...
05/21/2026
Oncology
News
Safety Outcomes of Bendamustine Treatment Among Patients With Indolent Non-Hodgkin Lymphoma in Real-World Setting
03/22/2024

Jordan Kadish

Jordan Kadish
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial...
03/22/2024
Oncology
News
Trastuzumab Rezetecan Improves Progression-Free Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
07/10/2026
Stephanie Holland
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase...
07/10/2026
Oncology
FDA Approval
FDA Approves Subcutaneous Isatuximab Across Multiple Indications for Patients With Multiple Myeloma
07/10/2026
Emily Estrada
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
The FDA has approved...
07/10/2026
Oncology
News
Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study...
07/09/2026
Oncology
News
Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer
07/09/2026
Stephanie Holland
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE...
07/09/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors
07/09/2026
Emily Estrada
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug...
07/09/2026
Oncology
News
Brain Radiotherapy Plus Continued Systemic Therapy Improves Survival in Brain-Only Progressive Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter...
07/09/2026
Oncology
News
Dose-Escalation Study Supports Phase 2 Development of BMS-986205 Plus Radiotherapy and Nivolumab in Glioblastoma
07/09/2026
Stephanie Holland
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial...
07/09/2026
Oncology
News
First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia
07/09/2026
Stephanie Holland
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase...
07/09/2026
Oncology
News
Imetelstat Maintains Overall Survival Advantage Over Best Available Therapy in JAK Inhibitor–Relapsed or Refractory Myelofibrosis
07/09/2026
Stephanie Holland
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc...
07/09/2026
Oncology
News
Aglatimagene Plus Radiotherapy Improves Disease-Free Survival in Localized Prostate Cancer
07/09/2026
Emily Estrada
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
Results from the phase 3 PrTK03...
07/09/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use